SOUTH WINDSOR, Conn., March 20, 2018 -- Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM™), today announced that the Company has been granted Accreditation of Foreign Medical Device Manufacturer by the Japanese Ministry of Health, Labour and Welfare. This accreditation lays the groundwork for OPM’s expansion into the rapidly growing Asian healthcare market.
OPM’s OsteoFab® technology, which combines laser melting additive manufacturing technology, and OPM's proprietary OXPEKK® material formulations, offers 3D printed poly-ether-ketone-ketone (PEKK)-based medical implants addressing craniomaxillofacial (CMF), spine and other emerging orthopedic and neurologic indications. OPM’s OsteoFab products are currently sold on a global basis via various partnership arrangements.
The healthcare industry in Asia currently represents approximately 25% of the nearly $2 trillion global healthcare market and is expected to grow by 11.1% to $517 billion in 2018, representing one of the fastest growing regions in the world, according to Frost & Sullivan. OPM has long identified Asia as an attractive market as a result of demographic trends and a predictable regulatory and reimbursement environment. Additionally, Japanese healthcare companies have a deep appreciation for advanced technologies that can cost-effectively address the need for patient-specific medical solutions and improved clinical outcomes.
“OPM started regular exploration of the Asian market 10 years ago in order to deeply understand the reimbursement environments, potential markets and commercialization opportunities,” said Scott DeFelice, Chief Executive Officer and Chairman of the Board of Oxford Performance Materials. “This accreditation allows OPM to start an export program to initiate market development and advance our Asian business.”
About Oxford Performance Materials, Inc.
A recognized leader in advanced materials science, Oxford Performance Materials Inc. (OPM) was founded in 2000 to exploit and commercialize the world’s highest performing thermoplastics, with a focus on poly-ether-ketone-ketone (PEKK). OPM develops proprietary material, process, and application technologies and applies high performance additive manufacturing (HPAM™) to produce fully functional, end-use structural parts. OPM Biomedical is a pioneer in personalized medicine, 3D printing OsteoFab® cranial and facial implants as an OEM, and spinal implants and additional products on a contract manufacturing basis. OPM Biomedical is the first and only company to receive FDA 510(k) clearance to manufacture 3D printed patient-specific polymeric implants, and has a total of four 510(k) clearances in its portfolio. The OPM Materials business unit develops proprietary OXPEKK® thermoplastic products and other materials for biomedical, aerospace, defense, and industrial applications. For more information, please visit: www.oxfordpm.com
Company Contact:
Bernie Plishtin
Oxford Performance Materials
860-656-9446
[email protected]
Media Contact:
Cory Ziskind
ICR
646-277-1232
[email protected]


MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies
CIA-Linked Investor Helped Quantum Systems Expand in US
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
Honda, Nissan Eye Shared Vehicle Software Platform by 2029
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
Street Poller Media and The Boom of the Street Interview Ad Industry
Star Entertainment Shares Fall After A$307 Million FY2026 Loss
OpenAI Rejects Apple Trade Secret Theft Claims
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says
Jefferies Names AMEC Top China Semiconductor Equipment Pick
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question
Trump Says ExxonMobil Among Oil Majors Planning Venezuela Return
OpenAI Nears Astra AI Model Launch With Safety Focus
Shein Shares Slide 9% in Hong Kong IPO Debut 



